Inter-and Intraobserver Reproducibility of Cerebral Atrophy Assessment on MRI Scans with Hemispheric Infarcts

Pasquier, Florence; Leys, D.; Weerts, Jan G.E.; Mounier‐Véhier, F.; Barkhof, Frederik; Scheltens, Philip

doi:10.1159/000117270

Cited by 417 publications

(328 citation statements)

References 0 publications

Supporting

Mentioning

315

Contrasting

Unclassified

Order By: Relevance

“…White matter changes WMC were assessed on transverse FLAIR images according to the modified 4-point Fazekas scale ranging from 0 (no WMC) to 3 (large confluent WMC) (Fazekas et al, 1987). Frontal lobe atrophy was assessed on a FLAIR sequence according to the 4-point scale for global cortical atrophy-frontal subscale (GCA-F) ranging from 0 (no atrophy) to 3 (severe 'knife blade' atrophy) (Pasquier et al, 1996). Parietal atrophy (PA) was visually assessed by combining T1 weighted sagittal, T1 weighted coronal and axial FLAIR sequences, using Koedam score (Koedam et al, 2011), a 4 points scale ranging from 0 (no atrophy) to 3 (severe atrophy).…”

Section: Csf and Mri Measurementsmentioning

confidence: 99%

CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia

Enache

Solomon

Cavallin

et al. 2016

Neurobiology of Aging

View full text Add to dashboard Cite

PostprintThis is the accepted version of a paper published in Neurobiology of Aging. This paper has been peerreviewed but does not include the final publisher proof-corrections or journal pagination. Citation for the original published paper (version of record):Enache, D., Solomon, A., Cavallin, L., Kåreholt, I., Kramberger, M G. et al. (2016) CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia. Neurobiology of Aging AbstractThe aim of this study was to explore cross-sectional associations between CAIDE Dementia Risk Score and dementia-related CSF and neuroimaging biomarkers in 724 memory clinic patients without dementia from the Memory Clinic at Karolinska University Hospital Huddinge, Sweden. We additionally evaluated the score's capacity to predict dementia. Two risk score versions were calculated: one including age, gender, obesity, hyperlipidaemia, and hypertension; and one additionally including APOE ε4 carrier status. CSF was analysed for amyloid β (Aβ), total tau (t-tau), and phosphorylated tau (p-tau). Visual assessments of medial temporal lobe atrophy (MTA), global cortical atrophy-frontal subscale (GCA-F) and Fazekas scale for white matter changes (WMC) were performed. Higher CAIDE Dementia Risk Score (version without APOE) was significantly associated with higher t-tau, more severe MTA, WMC and GCA-F. Higher CAIDE Dementia Risk Score (version with APOE) was associated with reduced Aβ, more severe MTA and WMC. CAIDE Dementia Risk Score version with APOE seemed to predict dementia better in this memory clinic population with short follow-up than the version without APOE.3

show abstract

Section: Csf and Mri Measurementsmentioning

confidence: 99%

CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia

Enache

Solomon

Cavallin

et al. 2016

Neurobiology of Aging

View full text Add to dashboard Cite

show abstract

“…Scheltens's MTA scale [12]); the traditional read for FDG-PET (70%); and structured visual assessment for amyloid-PET (80%) [11]. Eighteen percent (6/33) of responders rated cerebrovascular disease on MR with a number of different structured visual scales such as Fazekas's [13], Wahlund's [14], and Pasquier's [15].…”

Section: Use Of Biomarkers and Reading Tools 331 Imaging Biomarkersmentioning

confidence: 99%

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Bocchetta

Galluzzi

Kehoe

et al. 2014

Alzheimer's & Dementia

Self Cite

View full text Add to dashboard Cite

We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Ab42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/ frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P , .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.

show abstract

“…We analyzed all lobes for focal atrophy, defined as a definite loss of parenchymal volume and sulcal dilation. 8 Cortex atrophy was scored as 0 (none), 1 (mild), or 2 (marked). The genu, body, and splenium of the corpus callosum, cerebellum, and brainstem were analyzed and scored as 0 (absence of atrophy) or 1 (presence of atrophy).…”

mentioning

confidence: 99%

MRI characteristics and scoring in HDLS due to CSF1R gene mutations

Sundal¹,

Gerpen²,

Nicholson³

et al. 2012

Neurology

View full text Add to dashboard Cite

Objective: To describe the brain MRI characteristics of hereditary diffuse leukoencephalopathy with spheroids (HDLS) with known mutations in the colony-stimulating factor 1 receptor gene (CSF1R) on chromosome 5. Methods:We reviewed 20 brain MRI scans of 15 patients with autopsy-or biopsy-verified HDLS and CSF1R mutations. We assessed sagittal T1-, axial T1-, T2-, proton density-weighted and axial fluid-attenuated inversion recovery images for distribution of white matter lesions (WMLs), gray matter involvement, and atrophy. We calculated a severity score based on a point system (0Ϫ57) for each MRI scan. Results:Of the patients, 93% (14 of 15) demonstrated localized WMLs with deep and subcortical involvement, whereas one patient revealed generalized WMLs. All WMLs were bilateral but asymmetric and predominantly frontal. Fourteen patients had a rapidly progressive clinical course with an initial MRI mean total severity score of 16.7 points (range 10Ϫ33.5). Gray matter pathology and brainstem atrophy were absent, and the corticospinal tracts were involved late in the disease course. There was no enhancement, and there was minimal cerebellar pathology. Conclusion:Recognition of the typical MRI patterns of HDLS and the use of an MRI severity score might help during the diagnostic evaluation to characterize the natural history and to monitor potential future treatments. Indicators of rapid disease progression were symptomatic disease onset before 45 years, female sex, WMLs extending beyond the frontal regions, a MRI severity score greater than 15 points, and mutation type of deletion. Neurology ® 2012;79:566-574 GLOSSARY CI ϭ confidence interval; CSF1R ϭ colony-stimulating factor 1 receptor; FLAIR ϭ fluid-attenuated inversion recovery; HDLS ϭ hereditary diffuse leukoencephalopathy with spheroids; MLD ϭ metachromatic leukodystrophy; MS ϭ multiple sclerosis; SI ϭ signal intensity; WM ϭ white matter; WNL ϭ white matter lesion; X-ALD ϭ X-linked adrenoleukodystrophy.

show abstract

Inter-and Intraobserver Reproducibility of Cerebral Atrophy Assessment on MRI Scans with Hemispheric Infarcts

Cited by 417 publications

References 0 publications

CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia

CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

MRI characteristics and scoring in HDLS due to CSF1R gene mutations

Contact Info

Product

Resources

About